Abstract
The outbreaks of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in 2019, have highlighted the concerns about the lack of potential vaccines or antivirals approved for inhibition of CoVs infection. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) which is almost preserved across different viral species can be a potential target for development of antiviral drugs, including nucleoside analogues (NA). However, ExoN proofreading activity of CoVs leads to their protection from several NAs. Therefore, potential platforms based on the development of efficient NAs with broad-spectrum efficacy against human CoVs should be explored. This study was then aimed to present an overview on the development of NAs-based drug repurposing for targeting SARS-CoV-2 RdRp by computational analysis. Afterwards, the clinical development of some NAs including Favipiravir, Sofosbuvir, Ribavirin, Tenofovir, and Remdesivir as potential inhibitors of RdRp, were surveyed. Overall, exploring broad-spectrum NAs as promising inhibitors of RdRp may provide useful information about the identification of potential antiviral repurposed drugs against SARS-CoV-2.
Keywords: Antiviral; COVID-19; Drug; Nucleoside analogue; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, Antiviral, drug, nucleoside analogue, 【초록키워드】 SARS-CoV-2, Efficacy, Vaccine, Antiviral, antiviral drugs, Infection, Remdesivir, Favipiravir, drug, ribavirin, sofosbuvir, Repurposed drug, Severe acute respiratory syndrome, outbreak, RdRP, CoV, SARS-CoV-2 RNA, RNA polymerase, inhibitor, information, platform, severe acute respiratory syndrome-coronavirus-2, SARS-CoV-2 RdRp, Nucleoside analogues, tenofovir, CoVs, human CoVs, clinical development, nucleoside, ExoN, computational analysis, human CoV, lack, approved, ExoN proofreading, preserved, 【제목키워드】 SARS-CoV-2 RNA, Interaction,